Ovulation Inducing Drugs Market Growth Report 2024-2033: Research, Size, Demand, Analysis, and Insights

"The new report published by The Business Research Company, titled ""Ovulation Inducing Drugs Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the ovulation inducing drugs market size has grown strongly in recent years. It will grow from $4.11 billion in 2023 to $4.42 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The ovulation inducing drugs market size is expected to see strong growth in the next few years. It will grow to $5.7 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13256&type=smp

Rising Prevalence Of Women's Infertility Drives Growth In The Ovulation-Inducing Drug Market
The increasing prevalence of women's infertility is expected to propel the growth of the ovulation-inducing drug market. Women's infertility refers to the biological condition in which a woman cannot conceive a pregnancy or carry it to full term despite engaging in regular, unprotected sexual intercourse for an extended period, typically around a year or more. Ovulation-inducing drugs are used to treat women's infertility to address irregular or absent ovulation issues. These drugs target the hormonal pathways involved in the ovulation process and stimulate the ovaries to release mature eggs. For instance, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2022, there will be 6.1 million women between the ages of 15 and 44 in the US who have trouble becoming pregnant, equivalent to 10% of all women. Furthermore, in June 2022, according to CCRM Management Company LLC, a US medical management company, infertility affects 1 in 4 couples globally on average, rising by 5% to 10% each year. Therefore, the increasing prevalence of women's infertility drives the growth of the ovulation-inducing drug market.

Increasing Focus On Drug Developments To Drive The Revenues
Major companies operating in the ovulation-inducing drugs market are developing innovative drugs such as Cetrorelix acetate and getting approval to treat women undergoing controlled ovarian stimulation. Cetrorelix acetate for injection (cetrorelix) is a gonadotropin-releasing hormone (GnRH) antagonist. It prevents premature ovulation in women undergoing in vitro fertilization (IVF). For instance, in August 2022, Akorn Operating Company LLC, a US-based pharmaceutical company, received FDA approval for a generic version of cetrorelix acetate for injection, 0.25 mg (Cetrorelix). This is the initial AP-rated bioequivalent Merck Serono Cetrotide variant that has been authorized. Cetrorelix acetate is a GnRH antagonist that acts by blocking the effects of the gonadotropin-releasing hormone (GnRH). GnRH promotes the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. Moreover, it is used to prevent premature LH surges in women undergoing controlled ovarian stimulation (COS) and to help ensure that all of the eggs have a chance to mature.

The ovulation inducing drugs market covered in this report is segmented -

1) By Drug Class: Hormones, Therapeutics Drugs
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3) By End-User: Hospital, Homecare, Specialty Clinics, Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13256&type=discount

Major companies operating in the ovulation inducing drugs market report are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Abbvie Inc., Novartis AG, Bayer AG, Sanofi SA, Abbott Laboratories, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical Inc., Mylan N.V, Astellas Pharma Inc., Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Dr Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Endo International Inc., Ferring Pharmaceuticals Inc., Lupin Limited, LIVZON Pharmaceutical Group Inc., Torrent Pharmaceuticals Ltd., Gedeon Richter plc, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Zydus Pharmaceuticals (USA) Inc., Serum Institute of India Ltd., EMD Serono Inc., Cipla Inc.

Contents of the report:
1. Executive Summary
2. Ovulation Inducing Drugs Market Report Structure
3. Ovulation Inducing Drugs Market Trends And Strategies
4. Ovulation Inducing Drugs Market - Macro Economic Scenario
5. Ovulation Inducing Drugs Market Size And Growth
…..
27. Ovulation Inducing Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/ovulation-inducing-drugs-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

"Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide."

This release was published on openPR.